TGF-β and Iron Differently Alter HBV Replication in Human Hepatocytes through TGF-β/BMP Signaling and Cellular MicroRNA Expression

Sun O. Park1, Mukesh Kumar1, Sanjeev Gupta1,2,3*

1 Department of Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States of America, 2 Department of Pathology, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States of America, 3 Marion Bessin Liver Research Center, Cancer Center, Diabetes Research Center, Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, and Institute for Clinical and Translational Research, Bronx, New York, United States of America

Abstract

The nature of host-virus interactions in hepatitis B virus infection is incompletely understood. Since soluble factors, e.g., cytokines and metals, may exacerbate liver injury in chronic hepatitis, we considered that defining the effects of receptor-mediated signaling upon viral replication will be significant. Consequently, we studied effects of iron or TGF-β-induced TGF-β/BMP signaling in the HepG2 2.2.15 cell model of hepatitis B virus replication. We found iron and TGF-β increased hepcidin mRNA expression or TGF-β receptor kinase activity, respectively, which indicated that 2.2.15 cells responded appropriately to these substances. However, iron increased but TGF-β decreased hepatitis B virus mRNA and DNA expression. TGF-β induced expression at the mRNA level of multiple TGF-β/BMP pathway genes. This change was not observed in iron-treated cells. On the other hand, presence of SMAD proteins in iron or TGF-β-treated cells, including of SMAD4, did confirm convergence of TGF-β/BMP signaling pathways under these conditions. Since transcription factors in TGF-β/BMP signaling pathways could not have directly targeted hepatitis B virus itself, we studied whether iron or TGF-β exerted their effects through alternative mechanisms, such as by involvement of antiviral cellular microRNAs. We discovered cellular microRNA expression profiles were significantly different in iron or TGF-β-treated cells compared with untreated control cells. In many cases, exposure to iron or TGF-β changed microRNA expression in opposite directions. Introduction in cells of sequences representing such differentially expressed microRNAs, e.g., hsa-miR-125a-5p and -151-5p, even reproduced effects on virus replication of iron- or TGF-β. We surmised that TGF-β/BMP pathway members, i.e., SMADs, likely governed iron or TGF-β-induced microRNA expression. Iron may have mediated Drosophila/DGC/hibem-mediated processing of microRNAs. In turn, cellular microRNAs regulated replication of hepatitis B virus in iron or TGF-β-treated cells. This knowledge should advance studies of mechanisms in viral-host interactions, hepatic injury, and therapeutic developments for hepatitis B.

Introduction

Intra- and extracellular soluble signaling molecules are involved in hepatitis virus replication but these interactions are not well understood. For instance, inflammatory cytokines affect hepatitis B virus (HBV) replication by recruiting more than one signaling pathways. Among these, interleukins (e.g., IL12, IL18) may inhibit HBV replication, including with recruitment of interferon (IFN)-γ released from NK or T cells [1,2]. Interferon-α has widely been used for treating HBV with JAK/STAT signaling serving intermediary roles [3]. The role of these intracellular signaling pathways in transducing antiviral effects of interferon is far from complete and new information is still emerging [4]. Other cytokine pathways off note include tumor necrosis factor-α, which suppressed HBV replication [5]. Also, transforming growth factor (TGF-β) inhibited HBV replication [6], presumably with involvement of TGF-β signaling through SMAD-2 and -3 [7]. The canonical TGF-β signaling pathways involve SMADs -2 and -3 compared with bone morphogenetic protein (BMP) signaling via SMAD-1, -5, and -8. Nonetheless, after activation of TGF-β/BMP receptors leads to heteromeric complexing between SMADs, followed by engagement with the common-mediator, SMAD-4, which is required and sufficient for regulation of nuclear transcription, and in this way, brings together TGF-β/BMP signaling pathways. How these diverse intracellular signaling pathways may regulate replication of HBV (or other viruses) is yet to be clarified.

Disease-modifying cofactors, e.g., iron, are capable of altering HBV replication. In clinical studies, elevated hepatic iron content has been associated with higher prevalence of HBV infection [8], as well as worse outcomes in chronic hepatitis [9]. However, the molecular basis by which iron may alter HBV replication is unknown. Recently, hepatic release of hepcidin was found to be important in iron homeostasis, by decreasing intestinal iron...
absorption as well as hepatic iron uptake. As hepcidin exerts its intracellular effects by TGF-β/BMP signaling [10], a relationship emerged between this molecule and other intracellular mediators of cytokines. Unexpected signaling mechanisms were found to regulate hepcidin expression, e.g., epidermal growth factor, and also hepatocyte growth factor, which transduced their effects on hepcidin through PI3 kinase or MEK/ERK pathways [11]. Interestingly, iron-induced hepcidin expression altered HCV replication in cultured cells [12].

Therefore, intracellular signaling pathways could regulate hepatitis virus replication in many ways. More knowledge in this area will be significant for virus-host interactions and hepatic injury. Also, cytokines, chemokines and receptors expressed during host-viral interactions have elicited interest as targets for antiviral therapies [13].

Here, we reasoned that study of intersections in signaling by cytokines, e.g., TGF-β, on the one hand, and signaling by small molecules, e.g., iron, on the other hand, would help clarify mechanisms in HBV replication. One possibility was that iron and TGF-β exerted their effects by mechanisms completely independent of one another. Another possibility was that these molecules shared common intermediaries but that were regulated differently.

We used HepG2 2.2.15 cells for our studies since these express stably transduced HBV genomes with virus replication and have been suitable for mechanistic studies in vitro [14,15]. This cell line model permitted us to characterize the effects of TGF-β and iron on HBV replication, to demonstrate activation of intracellular signaling along TGF-β and BMP pathways, and to establish potential effector mechanisms in regulation of HBV replication.

Materials and Methods

Cytokines and Chemicals

We purchased TGF-β (R&D Systems, Minneapolis, MN) and ferrous sulfate heptahydrate (Sigma Chemical Co., St. Louis, MO), TGF-β1 receptor kinase inhibitor (TKI), LY-2157299 (Eli Lilly and Co., Indianapolis, IN) was from Dr. A. Verma at Einstein. All reagents and chemicals were from Sigma.

Cells

HepG2 2.2.15 cells were derived from HepG2 cells stably transfected with full-length HBV genomes [14]. HepG2 cells were originally from American Type Culture Collection (ATCC, Manassas, VA). Cells were cultured in Dulbecco’s Modified Eagle’s medium with 10% fetal bovine serum, 1% glutamine, 1% antibiotics (DMEM). After dose-ranging studies, we used 20 ng/ml TGF-β, 100 μM iron or 480 ng/ml TKI with cell culture for up to 48 h. For assays, cells were lysed in 100 mM Tris-HCl, pH 8.0, 0.2% Nonidet P-40 and 480 ng/ml TKI with cell culture for up to 48 h. For assays, cells and TGF-β molecules, e.g., iron, on the other hand, would help clarify TGF-β. This cell line model permitted us to characterize the effects of cytokines, e.g., TGF-β, on the one hand, and signaling by small molecules, e.g., iron, on the other hand, would help clarify mechanisms in HBV replication. One possibility was that iron and TGF-β exerted their effects by mechanisms completely independent of one another. Another possibility was that these molecules shared common intermediaries but that were regulated differently.

We used HepG2 2.2.15 cells for our studies since these express stably transduced HBV genomes with virus replication and have been suitable for mechanistic studies in vitro [14,15]. This cell line model permitted us to characterize the effects of TGF-β and iron on HBV replication, to demonstrate activation of intracellular signaling along TGF-β and BMP pathways, and to establish potential effector mechanisms in regulation of HBV replication.

Materials and Methods

Cytokines and Chemicals

We purchased TGF-β (R&D Systems, Minneapolis, MN) and ferrous sulfate heptahydrate (Sigma Chemical Co., St. Louis, MO), TGF-β1 receptor kinase inhibitor (TKI), LY-2157299 (Eli Lilly and Co., Indianapolis, IN) was from Dr. A. Verma at Einstein. All reagents and chemicals were from Sigma.

Cells

HepG2 2.2.15 cells were derived from HepG2 cells stably transfected with full-length HBV genomes [14]. HepG2 cells were originally from American Type Culture Collection (ATCC, Manassas, VA). Cells were cultured in Dulbecco’s Modified Eagle’s medium with 10% fetal bovine serum, 1% glutamine, 1% nonessential amino acids, and antibiotics (DMEM). After dose-ranging studies, we used 20 ng/ml TGF-β, 100 μM iron or 480 ng/ml TKI with cell culture for up to 48 h. For assays, cells were lysed in 100 mM Tris-HCl, pH 8.0, 0.2% Nonidet P-40 and protease inhibitors (Calbiochem Cocktail set III, EMD Biosciences, Darmstadt, Germany). Protein content was measured by Bradford Reagent (Pierce Research Products, Rockford, IL). To evaluate cell viability or changes in cell numbers, MTT assays were performed, as described previously [15].

HBV Assays

To demonstrate hepatitis B core antigen (HBeAg), cell lysates were resolved in 1.2% native agarose gels, followed by transfer to nylon membranes (Ambion, Life Technologies, Carlsbad, CA). HBeAg was detected with anti-HBe (Dako, Carpinteria, CA), as described previously [14]. For southern blotting, protein-detergent complexes were precipitated in 2.5 M KCl, viral pellet was dissolved in Tris-EDTA, and incubated with proteinase K (Ambion) for 1 h at 37°C. DNA was extracted with phenol-chloroform and precipitated by ethanol. 20 μg DNAs were resolved in 1.2% agarose gels and transferred to nylon membranes (Ambion). To analyze HBV RNA with northern blotting, 20 μg total cellular RNAs were extracted by Trizol Reagent (Life Technologies), resolved in 1.0% formaldehyde-agarose, and transferred to nylon membranes (Ambion). Nonradioactive HBV probe was prepared with psoralen-Biotin labeling kit (Ambion), as described by the manufacturer, with full-length HBV DNA from EcoRI- linearized pCP10 plasmid [16]. Prehybridization and hybridization of blots was as described previously [15]. Northern blots were rehybridized with human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe, as described previously [15]. Replicate blots were quantified by densitometry.

TGF-β Receptor Kinase Activity

Cell lysates with 50 μg total proteins each were spotted onto nylon membranes (Ambion). Blots were probed with mouse anti-phospho-serine-threonine antibody (Cat#612548, BD Biosciences, San Diego, CA). Detection used anti-mouse IgG-peroxidase (Sigma) with chemiluminescence methods.

Cellular Gene Expression

Total cellular RNAs were isolated with TRIzol Reagent (Life Technologies). Hepcidin expression was analyzed by quantitative real-time (RT)-polymerase chain reactions (PCR) with SYBR Green master mix (Qiagen, Valencia, CA). cDNAs were prepared with Omniscript RT kit (Qiagen). Hepcidin primers were: sense 5'-CTGCAACCCCAGGACAGAG-3' and antisense 5'-GGAA-TAAATAGGAAAGGAGGG3'-3' [17]; GAPDH primers were: sense 5'-GCCCTTCAAGGATAGACCC-3' and antisense 5'-AGGGGTTGTCATGGCAGTCG-3'. PCR conditions were: 40 cycles of denaturation at 95°C×90 s, annealing at 60°C×10 s and elongation at 72°C×20 s. For TGF-β/BMP signaling pathways, an array with 34 genes was used for qRT-PCR (http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-035A.html, SA Biosciences, Gaithersburg, MD). cDNAs were prepared by RT2 First Strand Kit. Each condition was in triplicate. Relative gene expression was determined by 2(-ΔΔCt) method.

Immunostaining

Cells were fixed in methanol at −20°C. Receptor-activated phosphorylated forms of R-SMAD-2, -3 and -4 were stained with antibodies (Cat#3101, #9515, #9520, Cell Signaling, Danvers, MA), followed by detection with Alexa Fluor 633-conjugated goat anti-rabbit IgG (Molecular Probes, Life Technologies). Nuclei were counterstained by DAPI.

MicroRNA Studies

Profiles of microRNA expression were obtained in total cellular RNA samples by microfluidics approach with arrays (Sanger databases, versions 9.1 and 11.0; LC Sciences, Dallas, TX). Background was subtracted with regression-based mapping on 5–25% of lowest intensity data excluding blank spots. Transcripts with undetectable signals below 3× background, incorporating spot analysis parameters, were excluded. Later, we excluded transcripts with <500 arbitrary signals as these are not identified by qRT-PCR. RNA hybrids were examined in HBV subtype ayw (Genbank accession number x65257.1) with miRanda program using minimal free energy (mfe) below −12 kcal/mol and miRanda score of over 140 as selection criteria.
Figure 1. Effects of TGF-β and iron on 2.2.15 cells. Shown are studies with cells cultured in the presence of 20 ng/ml TGF-β or 100 μM iron for 48 h. (A) Hepcidin mRNA expression increased by several-fold in iron-treated cells and not in TGF-β-treated cells. These data are plotted on a natural log scale in comparison with controls. (B) Serine-threonine kinase activity in cells with increase after TGF-β. This increase in kinase activity was blocked...
Oligonucleotide mimics or antagonists of microRNA were from commercial source (Dharmacon, Thermo Fisher): 125-a-5p, UCCCUGAGACCCUUUAACCUGUGA; 151-5p, UCGAG-GAGCUCACAGUCUAGU. For transfections, cells were incubated for 6 h with 50–200 nM of oligonucleotides in lipofectamine (Invitrogen). Transfection efficiency was monitored with 100 nM of Silencer Cy3-labeled Negative Control #1 siRNA (AM4621, Ambion). Iron or TGF-β were added to cells 12 h after miRNA transfections. Cells were cultured with Iron or TGF-β for 48 h before analysis of HBV replication.

**Statistical Methods**

Data are shown as means ± standard errors. T-tests or analysis of variance (ANOVA) with Turkey’s multiple comparisons test were used with Prism 5 (GraphPAD 5.0, San Diego, CA). P values <0.05 were taken as significant. Critical studies were repeated 2–4 times.

**Results**

Iron Increased and TGF-β Decreased HBV Replication in 2.2.15 Cells

After initial dose-response studies, we chose to treat cells with 100 μM iron or 20 ng/ml TGF-β for 48 h. In response to TGF-β, cell proliferation decreased slightly with MTT utilization of 87 ± 9% versus 100% in untreated controls, but this was not statistically significant. By contrast, in response to iron, cell proliferation increased slightly with MTT utilization of 118 ± 6% versus 100% in untreated controls, which was also not statistically significant.

**Figure 2. Mapping of changes in TGF-β/BMP signaling.** Shows gene expression changes in 2.2.15 cells treated by 20 ng/ml TGF-β for 48 h versus untreated controls. Changes were mapped with curated pathways in Ingenuity Pathway Analysis. Genes with increased expression are shown in red color and genes with decreased expression are shown in blue relative to untreated control cells.

doi:10.1371/journal.pone.0039276.g002
We established that 2.2.15 cells showed appropriate responses to iron and TGF-β. In iron-treated cells, hepcidin mRNA expression increased by up to 360-fold, but this was unchanged in TGF-β-treated cells, p<0.05 (Fig. 1A). In TGF-β-treated cells, activity of TGF-β receptor serine-threonine kinase increased by up to 4-fold, p<0.05, and was blocked by TGF-β receptor kinase inhibitor (TKI) (Fig. 1B). Native agarose gel assays, including southern blotting of these gels, indicated iron increased HBV replication by 20–40% (Fig. 1C, 1D). By contrast, TGF-β exerted an effect opposite to iron, since HBV replication decreased by 10–30% in TGF-β-treated cells. Northern and southern analysis confirmed these opposite effects of iron and TGF-β on HBV RNA and DNA expression in 2.2.15 cells (Fig. 1E, 1F).

Table 1. Fold increase in TGF-β/BMP pathway gene expression versus untreated cells (NC = no change).

| Gene Groups          | Gene | Gene name                        | Iron | TGF-β |
|----------------------|------|----------------------------------|------|-------|
| TGF-β Superfamily    |      |                                  |      |       |
| Cytokines            | LEFTY1 | Left-right determination factor 1 | NC   | 339   |
|                      | NODAL | Nodal homolog (mouse)            | NC   | 40    |
|                      | LTBP2 | Latent transforming growth factor beta binding protein 2 | NC   | 30    |
|                      | TGBF2 | Transforming growth factor, beta 2 | NC   | 21    |
|                      | TGBF1 | Transforming growth factor, beta 1 | NC   | 13    |
|                      | INHA  | Inhibin, alpha                   | NC   | 11    |
|                      | INHBA | Inhibin, beta A                   | NC   | 5     |
|                      | BMP1  | Bone morphogenetic protein 1     | NC   | 5     |
|                      | LTBP1 | Latent transforming growth factor beta binding protein 1 | NC   | 4     |
|                      | INHB8 | Inhibin, beta B                   | NC   | 3     |
|                      | TGBF3 | Transforming growth factor, beta 3 | NC   | 3     |
| Receptors            | TGBF111 | Transforming growth factor beta 1 induced transcript 1 | NC   | 10    |
|                      | BMPR2 | Bone morphogenetic protein receptor, type II | NC | 8     |
|                      | ACVR1 | Activin A receptor, type 1       | NC   | 6     |
|                      | TGBF1 | Transforming growth factor, beta 1 receptor | NC | 5     |
|                      | BMPR1A | Bone morphogenetic protein receptor, type IA | NC | 2     |
| SMADs and Target     | JUNB  | Jun B proto-oncogene              | NC   | 43    |
| Genes                | PDGFβ | Platelet-derived growth factor beta polypeptide | NC | 16    |
|                      | CDKN2B | Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) | NC | 26    |
|                      | COL1A1 | Collagen, type I, alpha 1         | NC   | 14    |
|                      | ENG   | Endoglin                          | NC   | 12    |
|                      | IGF1  | Insulin-like growth factor 1      | NC   | 11    |
|                      | SERPINE1 | Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | NC | 11    |
|                      | FST   | Follistatin                        | NC   | 7     |
|                      | SOX4  | SRY (sex determining region Y)-box 4 | NC | 6     |
|                      | DLX2  | Distal-less homeobox 2            | NC   | 6     |
|                      | TGBF1 | Transforming growth factor, beta-induced, 68 kDa | NC | 6     |
|                      | BAMBI | BMP and activin membrane-bound inhibitor homolog | NC | 5     |
|                      | JUN   | Jun proto-oncogene                 | NC   | 5     |
|                      | RNU1X | Runt-related transcription factor 1 | NC | 4     |
|                      | SMAD3 | SMAD family member 3              | NC   | 4     |
|                      | CDKN1A | Cyclin-dependent kinase inhibitor 1A (p21, Cip1) | NC | 4     |
|                      | TGFIF | TGFβ-induced factor homeobox 1    | NC   | 4     |
|                      | SMURF1 | SMAD specific E3 ubiquitin protein ligase 1 | NC | 3     |
|                      | FOS   | FBJ murine osteosarcoma viral oncogene homolog | NC | 3     |
|                      | ID1   | Inhibitor of DNA binding 1        | NC   | 3     |
|                      | ITGB5 | Integrin, beta 5                  | NC   | 2     |
|                      | NBL1  | Neuroblastoma, suppression of tumorigenicity 1 | NC | 2     |
|                      | SMAD5 | SMAD family member 5              | NC   | 2     |
|                      | NBL1  | Neuroblastoma, suppression of tumorigenicity 1 | NC | 2     |

doi:10.1371/journal.pone.0039276.t001
Figure 3. Regulation of SMAD expression in cells. Cells were cultured with 20 ng/ml TGF-β, 100 μM iron, or 100 μM iron plus 480 ng/ml TKI for 48 h. Immunostaining of cultured cells is shown in representative images for phosphorylated SMAD-2 (A), SMAD-3 (B) and SMAD-4 (C) (red color with DAPI counterstaining of nuclei in blue color). Morphometric analysis of larger samples of cells is given in accompanying charts. TGF-β increased expression of SMAD-2 and SMAD-4 but not SMAD-3. By contrast, iron had no effect on expression of SMAD-2 or SMAD-3. However, iron increased SMAD-4 expression, which was partly blocked by TKI. These results indicated differences in the nature of intracellular signaling in cells treated with iron or TGF-β although activation of SMAD-4 by both iron and TGF-β indicated confluence of TGF-β/BMP signaling in these conditions. This was emphasized by lowering of SMAD-4 expression in cells treated with iron plus TKI. Orig. mag., x630.

doi:10.1371/journal.pone.0039276.g003
Table 2. Changes in microRNA expression versus control untreated cells.

| MicroRNA       | Log2 fold-change | MicroRNA       | Log2 fold-change |
|----------------|------------------|----------------|------------------|
| hsa-miR-106a   | -3.88            | hsa-miR-7a     | 2.66             |
| hsa-miR-1246   | -6.80            | hsa-miR-7b     | 7.20             |
| hsa-miR-125a-5p| -4.06            | hsa-miR-7c     | 6.33             |
| hsa-miR-1275   | -1.69            | hsa-miR-7d     | 3.6              |
| hsa-miR-128    | -2.74            | hsa-miR-7e     | 2.41             |
| hsa-miR-148a   | -7.64            | hsa-miR-7f     | 2.66             |
| hsa-miR-151-3p | -1.79            | hsa-miR-7g     | 1.58             |
| hsa-miR-151-5p | -2.06            | hsa-miR-7i     | 2.51             |
| hsa-miR-17     | -7.64            | hsa-miR-1224-5p| 4.17             |
| hsa-miR-18a    | -7.16            | hsa-miR-1228   | 5.51             |
| hsa-miR-192    | -4.64            | hsa-miR-1268   | 2.49             |
| hsa-miR-194    | -3.09            | hsa-miR-1305   | 3.93             |
| hsa-miR-200b   | -5.64            | hsa-miR-130a   | 2.58             |
| hsa-miR-20a    | -10.70           | hsa-miR-15b    | 1.14             |
| hsa-miR-20b    | -8.38            | hsa-miR-182    | 1.38             |
| hsa-miR-21     | -2.18            | hsa-miR-183    | 2.04             |
| hsa-miR-224    | -8.97            | hsa-miR-188-5p | 4.10             |
| hsa-miR-26a    | -1.79            | hsa-miR-195    | 5.68             |
| hsa-miR-320a   | -2.64            | hsa-miR-206    | 4.54             |
| hsa-miR-320b   | -2.18            | hsa-miR-210    | 3.42             |
| hsa-miR-320c   | -2.40            | hsa-miR-22     | 2.23             |
| hsa-miR-320d   | -2.47            | hsa-miR-23a    | 1.07             |
| hsa-miR-361-5p | -1.40            | hsa-miR-29c    | 4.09             |
| hsa-miR-423-5p | -1.40            | hsa-miR-300    | 3.97             |
| hsa-miR-454    | -7.16            | hsa-miR-30b    | 1.63             |
| hsa-miR-455-3p | -5.06            | hsa-miR-30c    | 2.20             |
| hsa-miR-605    | -5.64            | hsa-miR-31     | 8.58             |
| hsa-miR-638    | -1.12            | hsa-miR-34c-3p | 4.43             |
| hsa-miR-663    | -3.47            | hsa-miR-568    | 9.87             |
| hsa-miR-720    | -2.06            | hsa-miR-574-3p | 6.61             |
| hsa-miR-877    | -5.06            | hsa-miR-574-5p | 4.07             |
| hsa-miR-92a    | -5.06            | hsa-miR-595    | 5.29             |
| hsa-miR-92b    | -9.97            | hsa-miR-601    | 5.88             |
|                |                  | hsa-miR-765    | 4.47             |
|                |                  | hsa-miR-98     | 5.05             |
|                |                  | hsa-miR-99a    | 6.41             |

Transcriptional Changes in TGF-β/BMP Signaling Pathways

In iron-treated 2.2.15 cells, expression of genes in TGF-β/BMP signaling pathways were not different from control untreated cells. However, TGF-β-treated cells showed marked differences in gene expression (Table 1). We found multiple cytokines in TGF-β superfamily were expressed at higher levels, including left-right determination factor (339-fold) and Nodal (40-fold), which regulate embryonic development. Expression of several cytokines increased, including TGF-β1 (13-fold), TGF-β2 (21-fold), and TGF-β3 (3-fold), BMP1 (5-fold), latent TGF-β-binding proteins (14-fold), and activin receptor (2-fold). Similarly, expression increased of TGF-β and related receptors, including TGF-β1 (5-fold), TGF-β1-induced transcript 1 (10-fold), BMPRA1 (2-fold), BMPR2 (8-fold), and activin receptor 1 (6-fold). Moreover, increased expression was noted of TGF-β transducers, i.e., SMAD-3 (4-fold), SMAD-5 (2-fold), TGF-β-induced (6-fold), and TGF-β-induced factor homeobox 1 (4-fold). Several cell proliferation regulators were expressed more, i.e., Jun (5-fold), JunB (43-fold), Fos (3-fold), p15 (CDKN2B) (26-fold), p21 (CDKN1A) (4-fold), insulin-like growth factor-I (11-fold), TGF-β and platelet-derived growth factor B (16-fold). Extracellular matrix genes were expressed more, e.g., collagen, type 1, α1 (14-fold) and integrin βV (2-fold), which was consistent with fibrogenic-type changes in TGF-β-treated cells. To visualize these gene relationships, we mapped canonical TGF-β/BMP pathways (Fig. 2).

We did not determine the effects of TKI on TGF-β-induced gene expression because it successfully blocked TGF-β response in 2.2.15 cells. However, we studied whether TKI would alter cellular responses to iron. In cells treated by iron plus TKI, we found no increases in expression of TGF-β superfamily cytokines or receptors, although expression of Nodal, INHA and LTBP4 declined by 2–3-fold.

SMAD Protein Expression in Cells

We immunostained cells for phosphorylated SMAD-2, -3 and -4 proteins to confirm changes in TGF-β/BMP signaling. In untreated cells, SMAD-2 was observed occasionally in cell cytoplasm (Fig. 3A). Iron did not alter SMAD-2 expression. This was different in TGF-β-treated cells, since SMAD-2 was now expressed in 82% of cells, p<0.05, along with translocation of the protein in many cells to nuclei. By contrast, iron plus TKI did not affect SMAD-2 expression. SMAD-3 was expressed well under basal conditions and also in iron- or TGF-β-treated cells (Fig. 3B). Expression of SMAD-4 changed prominently with significant increases from basal levels in iron- (53%) or TGF-β-treated cells (57%), p<0.05. In cells treated with iron plus TKI, increases in SMAD-4 expression were limited (Fig. 3C).
sion after treatment of cells with either TGF-β or iron. SMAD-4 was largely in cytoplasm under all conditions.

Iron or TGF-β Altered Cellular miRNA Expression
To identify potential transducers of TGF-β/BMP signaling in HBV replication, we analyzed miRNA expression. We chose to study this mechanism because expression of HBV genes should not have been directly regulated by SMADs activated by TGF-β/BMP signaling. On the other hand, SMADs can regulate expression of cellular miRNA, which, in turn, could have altered HBV replication (see below).

In iron-treated cells, from a total of 814 miRNA, 33 and 36 miRNA were downregulated or upregulated, respectively, versus untreated control cells (Table 2). Decreased miRNA expression ranged from Log2 fold of −2.12 (hsa-miR-638) to −10.70 (hsa-miR-20a). Increased miRNA expression ranged from Log2 fold of 1.07 (hsa-miR-23a) to 9.87 (hsa-miR-568). In TGF-β-treated cells, changes were less prominent, with downregulation of 6 and upregulation of 12 miRNA versus untreated control cells. The

| miRNA       | HBV target (nt) and (HBV gene) | Mfe (kcal/mol) | miRanda score | Sequence alignment |
|-------------|--------------------------------|----------------|---------------|--------------------|
| hsa-let-7a  | 90–111 (P/S)                   | −18.6          | 153           | miRNA              |
|             |                                |                |               | 3' UGUAGAUUGUUGGAGUAGU 5' |
|             |                                |                |               | 5' CCGTGTCCGACTACT CGCTT 3' target |
| hsa-let-7d  | 91–111 (P/S)                   | −19.3          | 151           | miRNA              |
|             |                                |                |               | 3' UGUAGAUUGUUGGAGUAGU 5' |
|             |                                |                |               | 5' CCGTGTCCGACTACT CGCTT 3' target |
| 3075–3104   | (P/S)                          | −15.3          | 146           | miRNA              |
|             |                                |                |               | 5' UGUAGAC——UU——GGAGAUGGAAGA |
|             |                                |                |               | 5' ACTTT GCCGAAATCGCGCTCGCTC TCC 3' target |
| hsa-let-7e  | 3084–3104 (P/S)                | −20.4          | 154           | miRNA              |
|             |                                |                |               | 5' UGUAGAUUGUUGGAGUAGU 5' |
|             |                                |                |               | 5' GCAAATCGCC TTCTGCC TCC 3' target |
| 91–111      | (P/S)                          | −15.9          | 146           | miRNA              |
|             |                                |                |               | 5' UGUAGAUUGUUGGAGUAGU 5' |
|             |                                |                |               | 5' CCTG TTCCGACTACT CGCTT 3' target |
| hsa-miR-106a| 1568–1590 (P/X)                | −19            | 151           | miRNA              |
|             |                                |                |               | 3' CGAUGGAC-GUGACAUUCG CAGAAAA 5' |
|             |                                |                |               | 5' TCT GCCTGACCTT GT—GCACTTCG 3' target |
| hsa-miR-125a-5p| 1451–1472 (P/X)              | −19.36         | 151           | miRNA              |
|             |                                |                |               | 5' GGUCCAAUUUCCCAGAGUCCU 5' |
|             |                                |                |               | 5' CGC—GGACGCACCCGTCTCGGGGT 3' target |
| 3038–3065   | (P/S/X)                        | −18.4          | 161           | miRNA              |
|             |                                |                |               | 5' GGUCCAAUUUC——CCAGAGUCCU |
|             |                                |                |               | 5' TTGGTGGAGCCCTCAGGCTCAGGGGC 3' target |
| hsa-miR-148a| 130–154 (P/X)                  | −15.4          | 140           | miRNA              |
|             |                                |                |               | 3' UGUUUCAAGAACU——ACGUAGACU 5' |
|             |                                |                |               | 5' TCGAGGAT-TGGAGACCCGCTGCTGTA 3' target |
| hsa-miR-151 | 231–254 (P/S)                  | −12.2          | 144           | miRNA              |
|             |                                |                |               | 5' GGAGU-UCC——CGAAGUCAUCA |
|             |                                |                |               | 5' CCTCAATACCCGACAGAGGTCAG 3' target |
| hsa-miR-17  | 1568–1590 (P/X)                | −19.4          | 151           | miRNA              |
|             |                                |                |               | 3' UGUAGGAC-GUGACAUUCCUGUUAAAC 5' |
|             |                                |                |               | 5' TCTGCCTGACCTT GT—GCACTTCG 3' target |
| hsa-miR-18a | 1514–1535 (P/X)                | −14.2          | 144           | miRNA              |
|             |                                |                |               | 3' AUUGACGUGAUCAUCUGGUGAAU 5' |
|             |                                |                |               | 5' ACCGACCAAGGGGCGACCTCTCC 3' target |
| hsa-miR-20a | 1569–1590 (P/X)                | −16.7          | 149           | miRNA              |
|             |                                |                |               | 3' GAUGGACGUGAUAAUUCGGAGAAU 5' |
|             |                                |                |               | 5' CCTGGCCTGACCTT GT—GCACTTCG 3' target |
| hsa-miR-20b | 1569–1590 (P/X)                | −19.6          | 155           | miRNA              |
|             |                                |                |               | 3' GAUGGACGUGAUACUCUGUGA 5' |
|             |                                |                |               | 5' CCTGGCCTGACCTT GT—GCACTTCG 3' target |
| hsa-miR-224 | 281–304 (P/X)                  | −20.3          | 144           | miRNA              |
|             |                                |                |               | 3' AUUGGCUUUGGUGAU——CAUUGAAC 5' |
|             |                                |                |               | 5' TAGGGGAATACCTCGTGTTGCTCGT 3' target |
| hsa-miR-483 | 1726–1744 (X)                  | −21.4          | 145           | miRNA              |
|             |                                |                |               | 3' UCUCUUGCCUCUCUCUCUCUCUCACU 5' |
|             |                                |                |               | 5' TAAAGACTGG——GAGGAGTTG 3' target |

P, polymerase, S, surface, and X, X open reading frames of HBV.

Table 3. Properties of miRNA capable of targeting HBV.

doi:10.1371/journal.pone.0039276.t003
Figure 4. Regulation of HBV replication by agarose gel analysis in cells treated with miRNA. For these studies, 2.2.15 cells were transfected with miRNA mimics or miRNA antagonists followed by administration to transduced cells of either 20 ng/ml TGF-β or 100 μM iron for 48 h. (A) Changes in iron-treated cells are shown after expression of miR-125a-5p or -151-5p mimics. These mimics dose-dependently decreased HBV replication in iron-treated cells. (B) Changes in TGF-β-treated cells are shown after expression of miR-125a-5p and miR-151-5p antagonists. These antagonists dose-dependently reversed TGF-β-induced inhibition of HBV replication. This substantiated the role of intracellular miRNA in regulation of HBV replication by iron or TGF-β.

doi:10.1371/journal.pone.0039276.g004
level of miRNA expression change was also lower, since Log2 fold changes ranged from -1.25 (hsa-miR-221) to -4.64 (hsa-miR-605) and Log2 fold increases ranged from 1.14 (hsa-miR-23b) to 2.67 (hsa-miR-125a-5p).

Of 6 downregulated miRNA in TGF-β-treated cells, 5 were also downregulated in iron-treated cells: hsa-miR-20b, -605, -630, 663, and -720. Expression of hsa-miR-221 was unchanged in iron-treated cells. Expression of 12 miRNA upregulated in TGF-β-treated cells both resembled and differed in iron-treated cells: 6 miRNA were similarly upregulated, hsa-miR-7a, -7d, -7e, -23a, -30c, and -574-5p; 2 miRNA were downregulated, hsa-miR-125a-5p and -71; and expression of 4 miRNA was unchanged, hsa-miR-146a, -23b, -483-5p, and -99b. The counter-regulation in TGF-β- and iron-treated cells of hsa-miR-125a-5p and -21 was of interest, since these, and other miRNA, may have contributed in HBV replication. RNA hybrid analysis of miRNA listed in Table 2 identified alignment of 13 miRNA with HBV domains (Table 3; hsa-let-7a, -7d, -7e, -106a, -125a-5p, -148a, -151, -17, -18a, -20a, -20b, -224, and -483).

**Regulation of HBV Replication by miRNA Sequences**

We selected miR-125a-5p and -151-5p for analyzing their effects on HBV replication. These miRNA are considered to interfere with HBV replication [18,19]. In response to miR-125a-5p and -151-5p mimics, iron-induced HBV replication declined in a dose-dependent fashion by up to 23% and 45%, respectively, p<0.05 (Fig. 4A). Expression of miR-125a-5p and -151-5p antagonists did not affect iron-induced HBV replication. Treatment of cells with antagonists of miR-125a-5p did not reverse TGF-β-induced suppression of HBV replication (Fig. 4B). However, antagonist of miR-151-3p reversed TGF-β-induced suppression of HBV replication. Mimics of miR-125a-5p and -151-5p did not affect TGF-β-induced inhibition of HBV replication. This confirmed that individual miRNAs were capable of altering HBV replication.

**Discussion**

These studies established 22.15 cells were appropriately responsive to iron and TGF-β. In case of iron, this was evidenced by greater hepcidin expression, which is transcriptionally regulated via BMP signaling [20], and requires the cofactors, hemoujuvelin and neogenin [21]. Responsiveness to TGF-β was evidenced by receptor kinase activity blocked by TKI. TGF-β changed expression of TGF-β/BMP pathway genes and targets, along with increases in phosphorylated SMAD-2, -3, and -4, as was anticipated. Iron did not alter expression of TGF-β/BMP pathway genes at mRNA levels but SMAD-4 expression linked TGF-β and BMP signaling pathways in iron-treated cells [7]. Despite association of iron with unfavorable outcomes in people with HBV [8,9], underlying mechanisms directing HBV replication were unknown. Previously, depletion of iron in HepG2 cells decreased HBV production [22]. This was consistent with increased HBV replication here in iron-treated HepG2 cells. We came across another study of TGF-β and HBV replication in HepG2 cells [6], where TGF-β decreased HBV replication, similar to our results. However, underlying mechanisms in how TGF-β directed HBV replication were unknown.

The role of TGF-β-induced SMADs in transcriptional controls was one possibility. Upon ligand-binding, the constitutively active type II TGF-β receptor phosphorylates type I TGF-β receptor, followed by recruitment of SMAD-2 and -3, which complex with SMAD-4 for transcriptional activation [7]. BMP receptors activate SMAD-1, -5 and -8, which too complex with SMAD-4 for transcriptional activation. Therefore, SMAD-4 connects TGF-β and BMP signaling. Under some situations, TGF-β- or BMP-specific SMADs may be simultaneously activated [23]. We considered that cellular miRNAs could have served intermediary roles in transducing the effects of TGF-β/BMP signaling on HBV replication. Recently, cellular miRNAs attracted much attention as ubiquitous antiviral regulators, including for HBV [18,19,24], miRNAs negatively regulate gene expression by sequence-specific binding of miRNAs followed by mRNA degradation or interference in mRNA translation. The identification of promoter sites in genomic regions encoding miRNAs, including SMAD-binding elements (SBE) [25,26], was noteworthy to us. Multiple miRNA were shown to contain SBE, e.g., hsa-let-7a, -7b, -7c, -7d, -7e, -7f, -21, -23b, etc. [26]. These miRNA were expressed in iron- or TGF-β-treated cells in our study. However, miRNA expression was different in iron- or TGF-β-treated cells. This difference was not explained by SMADs alone. Also, this difference was not explained by transcription factors regulating iron homeostasis, e.g., hemoujuvelin or neogenin, since these are not in cruciminer in mRNA transcription.

Another explanation was provided by mechanisms in processing of pri-miRNA to mature miRNA [27]. All canonical pri-miRNA undergo sequential cleavages in nucleus and cytoplasm by Dicer or Drosha RNAase III enzymes for maturation. Drosha requires the RNA-binding protein, DiGeorge Critical Region 8 (DGCGR8), for pre-miRNA cleavage. Recently, heme was identified as a constituent of Drosha-DGCGR8 complex, with the ionic state of heme-bound iron determining whether the complex will be capable of pri-miRNA cleavage [27]. In the ferric state, Drosha-DGCGR8-heme complex was highly stable and actively processed pri-miRNA to mature miRNA. By contrast, transition to ferrous state abolished pri-miRNA cleavage by Drosha-DGCGR8-heme complex. Thus, alterations in intracellular environment, leading to ferric or ferrous state of iron in Drosha-DGCGR8-heme complex, likely accounted for differential miRNA expression in iron- or TGF-β-treated cells.

The nature of miRNA-based host-virus interactions is evolving at present. Several anti-HBV miRNA were previously reported, e.g., hsa-miR-125-5p, -125b, -151-5p, -199a-3p, -199a-5p, -199b-3p, etc., including targets in polymerase, core, surface or X genes [15,18,19,28,29]. In chronic hepatitis B and HBV-associated HCC, several miRNA were also found in blood, including hsa-miR-7, -196b, -433, -511, with targets in polymerase or surface genes; hsa-miR-205, targeting X gene; and hsa-miR-345, targeting HBV preC gene [30]. Several of these were present in our list of miRNA expressed differentially in iron- or TGF-β-treated cells, whereas other miRNAs aligning with HBV sequences in our list had previously not been recognized.

Our miRNA expression studies showing modulation of the effects of iron- or TGF-β on HBV replication were instructive. As hsa-miR-125a-5p and -151-5p mimics prevented iron-induced increases in HBV replication, while their antagonists prevented TGF-β-induced decreases in HBV replication, this established miRNA were the principal intracellular effectors of TGF-β/BMP signaling.

Differentially expressed miRNA in iron-treated cells, and for that matter, TGF-β-treated cells, target genes widely, including pathways in cell stress and toxicity, cell proliferation, immune responses, metabolism, etc., which will be relevant for chronic hepatitis. Iron plays major roles in oxidative stress and cytoxicity, which coupled with perturbations in HBV replication, may alter natural history of hepatitis. TGF-β is especially significant for hepatic growth control and also for fibrosis.
Therefore, regulation of miRNA expression by iron and TGF-β will provide opportunities for understanding disease mechanisms in HBV-related liver injury and fibrosis. Moreover, mechanisms directing antiviral miRNA expression in iron- or TGF-β-treated cells should be helpful for drug development, according to considerations discussed previously by other investigators [27].

References

1. Cavanaugh VJ, Guidotti LG, Chisari FV (1997) Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 71: 3236–3243.
2. Kimura K, Kaki K, Wieland S, Guidotti LG, Chisari FV (2002) Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 76: 10702–10707.
3. Robek MD, Boyd BS, Wieland SF, Chisari FV (2004) Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci U S A 101: 1741–1747.
4. Park IH, Bark KW, Cho EY, Ahn BY (2011) PKR-dependent mechanisms of interferon-alpha for inhibiting hepatitis B virus replication. Mol Cells 32: 167–172.
5. Biermer M, Puro R, Schneider RJ (2003) Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol 77: 4033–4042.
6. Chou YC, Chen ML, Hu CP, Chen YL, Chong CL, et al. (2007) Transforming growth factor-beta1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA. Hepatology 46: 672–681.
7. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685–700.
8. Felton C, Lustbader ED, Merten C, Blumberg BS (1979) Serum iron levels and response to hepatitis B virus. Proc Natl Acad Sci U S A 76: 2438–2441.
9. Sebastiani G, Tempesta D, Alberti A (2012) Hepatic iron overload is common in patients with chronic hepatitis B and is more severe in patients coinfected with hepatitis D virus. J Viral Hepat 19: e170–176.
10. Hentze MW, Muckenthaler MU, Galy B, Camaschella C (2010) Two to tango: regulation of mammalian iron metabolism. Cell 142: 24–38.
11. Goodnough JB, Ramos E, Nem eh E, Ganz T (2012) Inhibition of hepcidin transcription by growth factors. Hepatology doi: 10.1002/hep.25615. [Epub ahead of print].
12. Bartolomei G, Cevik RE, Marcello A (2011) Modulation of hepatitis C virus replication by iron and hepcidin in HuH7 hepatocytes. J Gen Virol 92: 2072–2081.
13. Mauhi KN, Schafer H (2011) Overview of biologic response modifiers in infectious disease. Infect Dis Clin North Am 25: 723–731.
14. Sells MA, Chen ML, Acs G (1987) Production of hepatitis B virus particles in mouse cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 84: 1005–1009.
15. Kumar M, Follenzi A, Garforth S, Gupta S (2012) Control of HBV replication by antiviral miRNAs transferred by lentiviral vectors for potential cell and gene therapy approaches. Antiviral Ther 17: 519–28.
16. Dubois MF, Pourcel C, Rousset S, Chany C, Tiofiais P (1980) Excretion of hepatitis B surface antigen particles from mouse cells transformed with cloned viral DNA. Proc Natl Acad Sci U S A 77: 4549–4553.
17. Fein E, Merle U, Ehrealt R, Herrmann T, Kulakisz H (2007) Regulation of hepcidin in HepG2 and RINm5F cells. Peptides 28: 931–937.
18. Potenza N, Papa U, Mosca N, Zerbini F, Nobile V, et al. (2011) Human microRNA has-mir-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res 39: 5157–5163.
19. Liu AM, Zhang C, Burchard J, Fan ST, Wong KF, et al. (2011) Global regulation on microRNA in hepatitis B virus-associated hepatocellular carcinoma. OMICS 15: 187–91.
20. Truksa J, Peng H, Lee P, Beutler E (2006) Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci U S A 103: 10289–10293.
21. Zhang AS, Yang F, Wang J, Tsukamoto H, Enns CA (2009) Hemojuvelin-neogenin interaction is required for bone morphogenetic protein-4-induced hepcidin expression. J Biol Chem 284: 22580–22589.
22. Chouteau P, Le Seyec J, Sauder-Le Drea B, Canrie I, Brisset P, et al. (2001) Inhibition of hepatitis B virus production associated with high levels of intracellular viral DNA intermediates in iron-depleted HepG2/2.15 cells. J Hepatol 34: 108–113.
23. Murakami M, Kawachi H, Ogawa K, Nishio Y, Funahara M (2009) Receptor expression modulates the specificity of transforming growth factor-beta signaling pathways. Genes Cells 14: 469–482.
24. Davis-Dusenbery BN, Hata A (2011) Smad-mediated mRNA processing: a critical role for a conserved RNA sequence. RNA Biol 8: 71–76.
25. Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, et al. (2008) Chromatin structure analyses identify miRNA promoters. Genes Dev 22: 3172–3183.
26. Davis BN, Hillyard AG, Nguyen PH, Lagna G, Hata A (2010) Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell 39: 373–384.
27. Barr I, Smith AT, Chen Y, Senturia R, Burstyn JN, et al. (2012) Ferric, not ferrous, heme activates RNA-binding protein DGCR8 for primary microRNA processing. Proc Natl Acad Sci U S A 109: 1919–1924.
28. Zhang GL, Li YX, Zheng SQ, Liu M, Li X, et al. (2010) Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res 88: 169–175.
29. Chen Y, Shen A, Rider PJ, Yu Y, Wu K, et al. (2011) A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 25: 4511–4521.
30. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, et al. (2010) Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70: 9786–9807.

Author Contributions

Conceived and designed the experiments: SP MK. Analyzed the data: SP MK SG. Contributed reagents/materials/analysis tools: MK SG. Wrote the paper: SP SG.